News

This summer, the European Commission adopted a new Action Plan to tackle Antimicrobial Resistance (AMR) – a growing threat that is responsible for 25,000 deaths and a loss of €1.5 billion in the EU every year.

Today, the Innovative Medicines Initiative (IMI) is launching two new Calls for proposals with topics on Alzheimer’s disease, big data, vaccines, autoimmune disease, the blood-brain barrier, drug development, and the exploitation of IMI project results.

During the NADP launch event, we asked the scientific and business community to provide input on the aims and activities planned for NADP. What should NADP do for you?

Kees de Joncheere, chair of the NADP Executive Board and former Director of the Essential Medicines and Health Products Department at the World Health Organisation (WHO) is focused on the international opportunities for NADP. Over the last years increasing concern has been expressed at the international level over the threat of antimicrobial resistance, leading to the adoption of the Global Action Plan on AMR by the WHO World Health Assembly, and the UN General Assembly resolution on AMR in 2016.

An interview with Schelto Korf, NADP Alliance Manager

My role at the Netherlands Antibiotic Development Platform (NADP) as Alliance manager is to support academics and companies in finding new partners for collaboration in R&D of antibiotics and alternatives.